Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration

Critical Care Medicine

Volumn 26, Issue 1, 1998, Pages 184-187

  Gando, Satoshi ^a   Kameue, Takashi ^b   Nanzaki, Satoshi ^b   Hayakawa, Tatsuya ^b   Nakanishi, Yoshimi ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAPPORO CITY GENERAL HOSPITAL   (Japan)

Author keywords

Critical illness; Ganciclovir; Hemodiafiltration; Multiple organ dysfunction; Pharmacokinetics

Indexed keywords

FLUCONAZOLE; GANCICLOVIR; ISONIAZID; PREDNISONE; RIFAMPICIN; STREPTOMYCIN; VANCOMYCIN;

ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; CHRONIC KIDNEY FAILURE; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUBERCULOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ANTIMETABOLITES; BEHCET SYNDROME; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GLUCOCORTICOIDS; HALF-LIFE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; LUNG DISEASES; MIDDLE AGED; PREDNISOLONE;

EID: 0031985753     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199801000-00038     Document Type: Article

References (13)

1. Papazian L, Fraisse A, Garbe L, et al: Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology 1996; 84:280-287
2. Zimmerli W: Impaired host defense mechanisms in intensive care unit patients. Intensive Care Med 1985; 11:174-178
3. Crumpacker CS: Ganciclovir. N Engl J Med 1996; 335:721-729
4. Buhles WC, Mastre BJ, Tinker AJ, et al: Ganciclovir treatment of life- or sight-threatening Cytomegalovirus infection: Experience in 314 immuno-compromised patients. Reviews of Infectious Disease 1988; 10(Suppl): S495-S506
5. Sommadossi JP, Bevan R, Ling T, et al: Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Reviews of Infectious Disease 1988 (Suppl); 10:8507-8514
6. Lake KD, Fletcher CV, Love KR, et al: Ganciclovir pharmacokinetics during renal impairment. Antimicrob Agents Chemother 1988; 32:1899-1900
7. Combarnous F, Fouque D, Bernard N, et al: Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. Eur J Clin Pharmacol 1994; 46:379-381
8. Swan SK, Munar MY, Wigger MA, et al: Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am J Kidney Dis 1991; 17:69-72
9. Boulieu R, Bastien O, Bleyzac N: Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1993; 15:105-107
10. Bastien O, Boulieu R, Bleyzac N, et al: Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med 1994; 20:47-48
11. Yamaoka K, Tanigawa Y, Nakagawa T, et al: A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics 1981; 4:879-885
12. Paul S, Dummer S: Topics in clinical pharmacology: Ganciclovir. Am J Med Sci 1992; 304:272-277
13. Schetz M, Ferdinande P, Van den Berghe G, et al: Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21:612-620